CAMBRIDGE, Mass., May 08, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor conferences in May. Details are as follows:
Bank of America Merrill Lynch 2017 Health Care Conference
| Date: |
|
|
Wednesday, May 17, 2017 |
| Forum: |
|
|
Panel Discussion on Gene Therapy and Gene Editing |
| Time: |
|
|
4:40 p.m. ET |
| Location: |
|
|
Las Vegas |
UBS Global Healthcare Conference
| Date: |
|
|
Monday, May 22, 2017 |
| Forum: |
|
|
Company Presentation and Breakout Session |
| Time: |
|
|
8:00 a.m. ET |
| Location: |
|
|
New York |
A live webcast of the presentation will be available on the Investors & Media section of the Editas website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following the presentation.
About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.
Editas Media Contact
Dan Budwick
Pure Communications, Inc.
(973) 271-6085
dan@purecommunicationsinc.com
Editas Investor Contact
Mark Mullikin
Editas Medicine, Inc.
(617) 401-9083
mark.mullikin@editasmed.com
Editas Medicine
